New treatments for endometrial cancer
Development of new therapeutic approaches for endometrial cancer
This study is looking at a new treatment for advanced endometrial cancer that targets a specific pathway linked to cancer growth, and it aims to help patients, especially those who are obese, by developing a small molecule called EC359 that could improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10894701 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for endometrial cancer, particularly targeting the LIF/LIFR signaling pathway, which has been linked to cancer progression. The study aims to create a small molecule inhibitor, EC359, that could potentially block this pathway and improve outcomes for patients with advanced endometrial cancer. By analyzing gene expression data, the researchers are identifying key factors that contribute to cancer survival and recurrence, especially in patients who are obese. The approach combines laboratory research with insights from cancer databases to create targeted therapies that could complement existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include women diagnosed with advanced endometrial cancer, particularly those with type I and type II cancers.
Not a fit: Patients with early-stage endometrial cancer or those not diagnosed with endometrial cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced endometrial cancer, potentially reducing recurrence rates and improving survival.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Viswanadhapalli, Suryavathi — University of Texas Hlth Science Center
- Study coordinator: Viswanadhapalli, Suryavathi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.